Abstract
AbstractAlthough chemodynamic therapy (CDT) can effectively inhibit tumor growth and metastasis, it is challenging to eliminate tumors. Generally, CDT needs to combine with extra therapeutic modes for enhancing antitumor efficacy. Here, novel nanoparticles (BDTLAG NPs) are constructed via self‐assembly of cancer cell targeting prodrug (Bio‐PEG2K‐S‐S‐CPT), organic CDT agents (TPP‐PEG2K‐LND, TPP‐PEG2K‐TOS), pH‐responsive prodrug (PEG2K‐NH‐N‐DOX), T1‐enhanced magnetic resonance imaging contrast agents (Gd‐DTPA‐N16‐16), and anti‐angiogenic drug combrestatinA4 (CA4), realizing chemo(CT)‐chemodynamic combination therapy. The mechanism of BDTLAG NPs for enhancing antitumor efficacy involves: (i) BDTLAG NPs is accumulated in the tumor tissue by passive targeting; (ii) CA4 is released and specifically destroys angiogenesis, and the remaining BDTLG NPs enter the tumor cell via active targeting; (iii) the acid/glutathione (GSH)‐responsive prodrug release and GSH depletion; (iv) TPP‐PEG2K‐LND and TPP‐PEG2K‐TOS are accumulated in the tumor cell mitochondria due to mitochondria‐targeting, and is accompanied by endogenous reactive oxygen species bursts. This current strategy of single NPs that integrates spatiotemporally CT, CDT, GSH depletion, and MR imaging functions reflects the “all in one” concept, which provides a new opportunity for enhancing antitumor efficacy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
